Xeris Biopharma (XERS) News Today → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free XERS Stock Alerts $1.90 +0.01 (+0.53%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 1:52 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Stock Rating Reaffirmed by Piper SandlerMay 10, 2024 | markets.businessinsider.comStrong Operational Performance and Promising Prospects Affirm Buy Rating for Xeris PharmaceuticalsMay 10, 2024 | finance.yahoo.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comXeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst ChallengesMay 10, 2024 | marketbeat.comPiper Sandler Reaffirms Overweight Rating for Xeris Biopharma (NASDAQ:XERS)Piper Sandler reissued an "overweight" rating and set a $3.00 price target (down from $4.00) on shares of Xeris Biopharma in a report on Friday.May 10, 2024 | finance.yahoo.comXeris Biopharma Holdings First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comQ1 2024 Xeris Biopharma Holdings Inc Earnings CallMay 9, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)May 9, 2024 | investorplace.comXERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | proactiveinvestors.comXeris Biopharma sees 1Q revenue jump on strength of product salesMay 9, 2024 | msn.comXeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02, revenue of $40.64M misses by $1.17MMay 9, 2024 | finance.yahoo.comXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsMay 9, 2024 | seekingalpha.comXERS Xeris Biopharma Holdings, Inc.May 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Xeris Biopharma's earnings reportMay 8, 2024 | americanbankingnews.comXeris Biopharma (XERS) Scheduled to Post Earnings on ThursdayMay 6, 2024 | proactiveinvestors.comXeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetesMay 6, 2024 | businesswire.comXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsMay 3, 2024 | marketbeat.comXeris Biopharma (XERS) to Release Quarterly Earnings on ThursdayXeris Biopharma (NASDAQ:XERS) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 2, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings StockMay 2, 2024 | businesswire.comXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024April 5, 2024 | finance.yahoo.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsApril 3, 2024 | finance.yahoo.comXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 2, 2024 | finance.yahoo.comXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Now Covered by OppenheimerOppenheimer initiated coverage on shares of Xeris Biopharma in a report on Thursday. They issued an "outperform" rating and a $5.00 target price on the stock.March 18, 2024 | proactiveinvestors.comXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 GrowthMarch 9, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual ResultsMarch 8, 2024 | seekingalpha.comXeris Biopharma (XERS) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | marketbeat.comBrokers Offer Predictions for Xeris Biopharma Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 earnings estimates for shares of Xeris Biopharma in a research note issued to investors on Thursday, March 7th. HC Wainwright analyst O. Livnat forecasts that the companyMarch 7, 2024 | finance.yahoo.comXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023March 7, 2024 | insidermonkey.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | marketbeat.comHC Wainwright Boosts Xeris Biopharma (NASDAQ:XERS) Price Target to $6.00HC Wainwright lifted their price objective on shares of Xeris Biopharma from $5.50 to $6.00 and gave the stock a "buy" rating in a research note on Thursday.March 7, 2024 | finance.yahoo.comQ4 2023 Xeris Biopharma Holdings Inc Earnings CallMarch 6, 2024 | marketwatch.comXeris Biopharma Shares Drop After Weak 4Q ResultsMarch 6, 2024 | msn.comXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84MMarch 6, 2024 | investorplace.comXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023March 6, 2024 | proactiveinvestors.comXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpMarch 6, 2024 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Estimates By $0.01 EPSXeris Biopharma (NASDAQ:XERS - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Xeris Biopharma had a negative return on equity of 266.53% and a negative net margin of 40.48%. During the same period last year, the business earned ($0.10) EPS.March 6, 2024 | businesswire.comXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsMarch 6, 2024 | businesswire.comXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalFebruary 28, 2024 | businesswire.comXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024February 23, 2024 | theglobeandmail.com3 Breakout Stocks Under $5 to Buy for More UpsideFebruary 15, 2024 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Down 9.7% in JanuaryXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 9,400,000 shares, a decline of 9.7% from the January 15th total of 10,410,000 shares. Based on an average daily volume of 1,980,000 shares, the days-to-cover ratio is presently 4.7 days.February 8, 2024 | marketbeat.comFY2023 Earnings Forecast for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Issued By Leerink PartnrsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Analysts at Leerink Partnrs upped their FY2023 earnings per share (EPS) estimates for Xeris Biopharma in a research report issued on Monday, February 5th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earninFebruary 7, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Xeris Biopharma Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Xeris Biopharma in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz expects that the company will earn (February 5, 2024 | finance.yahoo.comXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceFebruary 3, 2024 | realmoney.thestreet.comBig Game or Small, Here's How to Go About Stalking a TradeJanuary 10, 2024 | marketwatch.comXeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease TreatmentJanuary 10, 2024 | marketwatch.comXeris Biopharma Shares Climb 12% on Amgen License AgreementJanuary 10, 2024 | msn.comWhy Is Xeris Biopharma (XERS) Stock Up 12% Today?January 10, 2024 | marketbeat.comTraders Buy Large Volume of Call Options on Xeris Biopharma (NASDAQ:XERS)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders bought 2,183 call options on the stock. This represents an increase of approximately 1,592% compared to the average daily volume of 129 call options. Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Did Intel Just Dethrone Nvidia? (Ad)Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. XERS Media Mentions By Week XERS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XERS News Sentiment▼-0.010.56▲Average Medical News Sentiment XERS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XERS Articles This Week▼192▲XERS Articles Average Week Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CTMX News XBIT News ENTA News RAPT News NKTR News ELYM News INZY News XOMA News VSTM News DSGN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XERS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
